Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates
09 févr. 2016 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported positive topline...